<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="402">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05155917</url>
  </required_header>
  <id_info>
    <org_study_id>210201</org_study_id>
    <nct_id>NCT05155917</nct_id>
  </id_info>
  <brief_title>Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care</brief_title>
  <official_title>Concurrent Subcutaneous Basal Insulin and Intravenous Insulin Pump in Hyperglycemic Crisis Patients Under Critical Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and efficacy of basal insulin during intravenous insulin infusion for&#xD;
      hyperglycemic crisis patients under critical care is still unknown.&#xD;
&#xD;
      We assumed that concurrent basal insulin subcutaneous injection and intravenous insulin&#xD;
      infusion for critically ill DKA and HHS patients would shorten the time of hyperglycemic&#xD;
      crisis correction and achieved better glycemic control(decrease hypoglycemia and rebound&#xD;
      hyperglycemia).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are hyperglycemic&#xD;
      crises sharing similar clinical features including hyperglycemia, dehydration and&#xD;
      electrolytes abnormalities. Hyperglycemia results from relative deficient circulating insulin&#xD;
      and oversecretion of glucagon, catecholamines, cortisol, and growth hormone. Glycosuria&#xD;
      induced osmotic diuresis leads to dehydration and electrolyte abnormalities. Diabetic&#xD;
      ketoacidosis is also characterized by increased gluconeogenesis, lipolysis, ketogenesis, and&#xD;
      decreased glycolysis.[1] In critically ill and mentally obtunded patients with DKA or&#xD;
      hyperosmolar hyperglycemia, continuous intravenous insulin is the standard of care.[2]&#xD;
      Administration of subcutaneous insulin glargine during intravenous insulin infusion shortened&#xD;
      the time of DKA correction and significantly decreased hyperglycemia after discontinuation of&#xD;
      the intravenous insulin. [3, 4]The differences in rebound hyperglycemia rates were highly&#xD;
      significant for at least 12 hours after transition to subcutaneous insulin regimens in the&#xD;
      DKA and non-DKA patients as well as in organ transplant patients receiving steroids. [4]&#xD;
      However, the previous studies only enrolled small numbers of patients(without Asian&#xD;
      population) and excluded newly diagnosed hyperglycemia or critical illness and pregnant&#xD;
      women. The safety and efficacy of basal insulin during intravenous insulin infusion for&#xD;
      hyperglycemic crisis patients under critical care is still unknown.&#xD;
&#xD;
      The investigators assumed that concurrent basal insulin subcutaneous injection and&#xD;
      intravenous insulin infusion for critically ill DKA and HHS patients would shorten the time&#xD;
      of hyperglycemic crisis correction and achieved better glycemic control(decrease hypoglycemia&#xD;
      and rebound hyperglycemia).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the rates of rebound hyperglycemia</measure>
    <time_frame>&quot;the next 12 hours&quot; after ceasing insulin infusion</time_frame>
    <description>the rates of hyperglycemia( serum glucose &gt;300mg/dl) after ceasing insulin infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the rates of hypoglycemia</measure>
    <time_frame>&quot;the next 12 hours&quot; after ceasing insulin infusion</time_frame>
    <description>the rates of hypoglycemia( serum glucose &lt;70mg/dl) during insulin infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin infusion time</measure>
    <time_frame>'the next 12 hours' after ceasing insulin infusion</time_frame>
    <description>hours of the total insulin infusion therapeutic time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>days of ICU admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ventilator use days</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>days of ventilator depending time(from intubation to extubation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Mortality rate</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>mortality rate during ICU admission</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hyperglycaemic Crisis in Diabetes Mellitus</condition>
  <condition>Diabetic Ketoacidosis</condition>
  <condition>Hyperglycaemic Hyperosmolar Nonketotic Syndrome</condition>
  <arm_group>
    <arm_group_label>basal insulin and insulin pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in the intervention group received insulin glargine sc (0.25 U/kg body weight) within 6 h of initiation of iv insulin infusion, as close to initiation of iv insulin as possible.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin pump</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group did not receive placebo injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine 300 UNT/ML [Toujeo]</intervention_name>
    <description>insulin glargine sc (0.25 U/kg body weight)</description>
    <arm_group_label>basal insulin and insulin pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with hyperglycemic crisis(DKA, HHS or mixing type) receiving iv insulin&#xD;
             infusion&#xD;
&#xD;
          -  Patients admitted to the Changhua Christian Hospital Medical Intensive Care Unit(MICU)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  age under 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YU FU LEE, college</last_name>
    <phone>886-4-7238595</phone>
    <phone_ext>3972</phone_ext>
    <email>181318@cch.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua city</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>YU FU LEE, college</last_name>
      <phone>+886-4-7238595</phone>
      <phone_ext>3972</phone_ext>
      <email>181318@cch.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Gosmanov AR, Gosmanova EO, Kitabchi AE. Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State. 2021 May 9. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dhatariya K, Dungan K, Hershman JM, Hofland J, Kalra S, Kaltsas G, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferr√®re B, Levy M, McGee EA, McLachlan R, Morley JE, New M, Purnell J, Sahay R, Singer F, Sperling MA, Stratakis CA, Trence DL, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from http://www.ncbi.nlm.nih.gov/books/NBK279052/</citation>
    <PMID>25905280</PMID>
  </results_reference>
  <results_reference>
    <citation>American Diabetes Association. 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020 Jan;43(Suppl 1):S193-S202. doi: 10.2337/dc20-S015. Review.</citation>
    <PMID>31862758</PMID>
  </results_reference>
  <results_reference>
    <citation>Shankar V, Haque A, Churchwell KB, Russell W. Insulin glargine supplementation during early management phase of diabetic ketoacidosis in children. Intensive Care Med. 2007 Jul;33(7):1173-1178. doi: 10.1007/s00134-007-0674-3. Epub 2007 May 17.</citation>
    <PMID>17508198</PMID>
  </results_reference>
  <results_reference>
    <citation>Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, Wang C, Kam I, Draznin B. Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia. J Clin Endocrinol Metab. 2012 Sep;97(9):3132-7. doi: 10.1210/jc.2012-1244. Epub 2012 Jun 8.</citation>
    <PMID>22685233</PMID>
  </results_reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>December 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 13, 2021</last_update_submitted>
  <last_update_submitted_qc>December 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperglycemic crisis</keyword>
  <keyword>DKA</keyword>
  <keyword>HHS</keyword>
  <keyword>insulin pump</keyword>
  <keyword>basal insulin</keyword>
  <keyword>critical care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

